Products

PPTINIB Tablet contains Dasatinib, a prescription tyrosine kinase inhibitor (TKI) used in the treatment of certain types of leukemia. It works by blocking abnormal proteins (BCR-ABL and SRC family kinases) that promote the growth and spread of cancer cells, helping to slow or stop disease progression. Dasatinib is commonly prescribed for adults and children with Philadelphia chromosome-positive (Ph+) Chronic Myeloid Leukemia (CML) and certain cases of Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL), as determined by an oncologist or hematologist. PPTINIB Tablets are manufactured under stringent quality standards and are available in multiple strengths to meet different treatment requirements. The tablets should be taken exactly as prescribed by a healthcare professional, with or without food, and treatment should not be discontinued without medical advice. Key Highlights Brand Name: PPTINIB Tablet Generic Name: Dasatinib Dosage Form: Oral Tablets Therapeutic Category: Anti-Cancer / Oncology Medicine Drug Class: Tyrosine Kinase Inhibitor (TKI) Indications: Philadelphia chromosome-positive Chronic Myeloid Leukemia (Ph+ CML) and Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL) Storage: Store below 30°C in a cool, dry place away from direct sunlight. Prescription Status: Prescription-only medicine. Use only under the supervision of a qualified healthcare professional.

Peg Zuvigrast (Pegfilgrastim Injection 6 mg) belongs to the Supportive Cancer Care category and is used to help reduce the risk of chemotherapy-induced neutropenia, a condition in which white blood cell counts become dangerously low after cancer treatment. Pegfilgrastim is a long-acting Granulocyte Colony-Stimulating Factor (G-CSF) that stimulates the bone marrow to produce neutrophils, helping the body fight infections during chemotherapy. This category includes Pegfilgrastim 6 mg injections intended for use in oncology hospitals, cancer treatment centers, specialty clinics, and licensed pharmacies. The medicine is typically administered under the supervision of qualified healthcare professionals as part of supportive care for patients receiving myelosuppressive chemotherapy. Our selection of Pegfilgrastim injections is manufactured in WHO-GMP compliant facilities and is available for international pharmaceutical export, wholesale distribution, and institutional procurement. Products are supplied with secure packaging and reliable worldwide shipping in accordance with applicable export regulations. Category Highlights Long-acting Pegfilgrastim (G-CSF) injection for supportive cancer care Helps reduce the risk of chemotherapy-induced neutropenia and febrile neutropenia 6 mg/0.6 mL prefilled syringe formulation Manufactured in WHO-GMP compliant pharmaceutical facilities Suitable for hospitals, oncology clinics, specialty pharmacies, and distributors Available for wholesale, institutional supply, and international export Secure packaging and reliable global shipping Prescription-only medicine to be used under the supervision of qualified healthcare professionals.

PEG-Asparaginase (Peg L-Asparaginase) Injection is an oncology medicine used as part of combination chemotherapy protocols for the treatment of Acute Lymphoblastic Leukemia (ALL) and certain other hematologic malignancies. It is a pegylated form of the enzyme L-asparaginase that works by depleting the amino acid L-asparagine, which leukemia cells require for growth and survival. Because healthy cells can produce their own asparagine while many leukemia cells cannot, PEG-Asparaginase selectively inhibits the growth of malignant cells. This category includes high-quality PEG L-Asparaginase injections manufactured in WHO-GMP compliant facilities and intended for use by hospitals, oncology centers, specialty pharmacies, and licensed healthcare providers. The medicine is administered by qualified healthcare professionals according to established chemotherapy protocols and requires careful patient monitoring due to the potential for serious adverse reactions. Our range of PEG-Asparaginase injections is available for international export, wholesale supply, and pharmaceutical distribution, with secure packaging and reliable worldwide shipping to eligible destinations in accordance with applicable regulations. Category Highlights: Pegylated L-Asparaginase injections for oncology treatment Used in combination chemotherapy for Acute Lymphoblastic Leukemia (ALL) WHO-GMP quality manufacturing Suitable for hospitals, oncology clinics, and specialty pharmacies Available for wholesale and international pharmaceutical export Secure packaging with reliable global shipping Prescription-only medicine to be administered under specialist medical supervision

Meracaptaz 50 mg contains Melphalan, an alkylating anticancer medicine used in the treatment of certain blood cancers and other selected malignancies. It works by damaging the DNA of rapidly dividing cancer cells, helping to slow or stop their growth. Melphalan tablets are prescribed only under the supervision of an experienced oncologist due to the risk of severe bone marrow suppression and the need for close monitoring. Key Benefits Helps treat specific cancers by inhibiting cancer cell growth. Oral tablet for convenient administration when prescribed. Commonly used in established chemotherapy protocols. May be used alone or in combination with other anticancer medicines. Treatment is individualized based on the patient's condition and response. Indications Meracaptaz (Melphalan Tablets) may be prescribed for: Multiple myeloma Ovarian cancer Other oncology indications as determined by the treating oncologist and local treatment guidelines. How It Works Melphalan belongs to the alkylating agent class of chemotherapy medicines. It forms cross-links with DNA, preventing cancer cells from replicating and dividing, which ultimately leads to cancer cell death. Dosage & Administration Take only as prescribed by your oncologist. Swallow the tablet whole with water. The dose depends on the type of cancer, body condition, and blood test results. Regular blood tests are essential during treatment to monitor blood cell counts and organ function. Do not change or stop the medication without medical advice. Possible Side Effects Common side effects may include: Low white blood cell count (neutropenia) Low platelet count (thrombocytopenia) Anemia Nausea and vomiting Loss of appetite Mouth sores Fatigue Increased risk of infections Seek immediate medical attention if you develop fever, unusual bleeding, severe bruising, persistent vomiting, or signs of a serious infection.

Melphalaz (Melphalan Injection 50 mg) is a chemotherapy medicine containing Melphalan, an alkylating agent used in the treatment of certain cancers. It works by damaging the DNA of rapidly dividing cancer cells, preventing their growth and multiplication. Melphalaz is administered by qualified healthcare professionals in hospitals or specialized oncology centers under the supervision of an experienced oncologist. Key Benefits Effective chemotherapy for selected blood cancers and other malignancies. Helps slow or stop the growth of cancer cells. Used as part of standard oncology treatment protocols. May be used alone or in combination with other anticancer medicines. Administered under strict medical supervision for optimal safety and efficacy. Indications Melphalaz (Melphalan Injection 50 mg) may be prescribed for: Multiple myeloma Ovarian cancer High-dose conditioning therapy before stem cell or bone marrow transplantation Other malignancies as determined by the treating oncologist How It Works Melphalan belongs to the alkylating agent class of chemotherapy drugs. It binds to the DNA of cancer cells, causing cross-linking that interferes with DNA replication and cell division. This ultimately leads to cancer cell death and helps control tumor growth. Dosage & Administration Administered only by trained healthcare professionals. The dosage is based on the patient's body weight, medical condition, laboratory values, and treatment protocol. Given by intravenous (IV) injection or infusion as directed by the oncologist. Patients should undergo regular blood tests during treatment to monitor blood cell counts and organ function. Possible Side Effects Common side effects may include: Low white blood cell count (neutropenia) Low platelet count (thrombocytopenia) Anemia Nausea and vomiting Mouth sores (mucositis) Loss of appetite Fatigue Increased risk of infection Hair thinning or hair loss (less common) Seek immediate medical attention if you develop fever, severe bleeding, difficulty breathing, allergic reactions, or signs of serious infection.

Lenvitib Cap contains Lenvatinib, an oral targeted anticancer medicine classified as a multi-kinase inhibitor (TKI). It works by blocking proteins that promote tumor growth and the formation of new blood vessels (angiogenesis), helping to slow or stop the progression of certain cancers. Lenvitib Capsules are prescribed by oncologists for the treatment of selected advanced or metastatic cancers, either alone or in combination with other anticancer therapies. Key Benefits Helps slow the growth and spread of cancer cells. Inhibits blood vessel formation that supplies tumors. Oral capsule for convenient at-home treatment as prescribed. Used in multiple cancer types based on clinical guidelines. Can be used alone or in combination with immunotherapy or other anticancer medicines in appropriate patients. Indications Lenvitib (Lenvatinib) Capsules may be prescribed for: Differentiated thyroid cancer (DTC) that is radioactive iodine-refractory. Advanced renal cell carcinoma (kidney cancer), in combination with other medicines where indicated. Hepatocellular carcinoma (liver cancer). Advanced endometrial cancer in combination therapy, as recommended by the treating oncologist. Other approved oncology indications according to local prescribing guidelines. How It Works Lenvatinib blocks multiple receptor tyrosine kinases, including VEGFR, FGFR, PDGFR, RET, and KIT. By inhibiting these pathways, it reduces tumor blood supply and slows cancer cell growth and spread. Dosage & Administration Take exactly as prescribed by your oncologist. Swallow the capsule whole with water, with or without food. Take it at the same time each day. Do not change the dose or stop treatment without medical advice. If a dose is missed, follow your healthcare provider's instructions. Possible Side Effects Common side effects may include: High blood pressure Fatigue Diarrhea Decreased appetite Weight loss Nausea or vomiting Mouth sores Hand-foot syndrome Protein in urine Seek immediate medical attention if you experience severe bleeding, chest pain, severe headache, shortness of breath, or signs of liver or kidney problems.

Graniz (Granisetron Hydrochloride Injection 3 mg) is a prescription medicine containing Granisetron Hydrochloride, a 5-HT3 (serotonin) receptor antagonist used to help prevent and treat nausea and vomiting associated with chemotherapy, radiotherapy, and surgery. It works by blocking serotonin receptors that trigger nausea and vomiting, providing effective symptom control during cancer treatment and the perioperative period. Graniz is administered by qualified healthcare professionals through intravenous (IV) injection or infusion. The dosage and timing are determined by the treating physician based on the patient's age, medical condition, and treatment regimen. Key Benefits Contains Granisetron Hydrochloride 3 mg, a proven antiemetic. Helps prevent chemotherapy-induced nausea and vomiting (CINV). Effective in reducing radiotherapy-induced nausea and vomiting (RINV). May be used to prevent and treat postoperative nausea and vomiting (PONV). Sterile injectable formulation for hospital and clinical use. Manufactured according to high pharmaceutical quality standards. Indications Graniz (Granisetron Hydrochloride Injection 3 mg) may be prescribed for: Prevention of chemotherapy-induced nausea and vomiting (CINV). Prevention and treatment of radiotherapy-induced nausea and vomiting (RINV). Prevention and treatment of postoperative nausea and vomiting (PONV). Administration For intravenous (IV) administration by trained healthcare professionals. Dosage is individualized based on the patient's clinical condition and treatment protocol. Follow the prescribing physician's instructions regarding administration and monitoring.

Erlonat Tablets contain Erlotinib, a prescription targeted anticancer medicine belonging to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) class. Erlotinib works by blocking EGFR signaling, which can slow or stop the growth of certain cancer cells that rely on this pathway. It is used only in specific clinical settings and under the supervision of an experienced oncologist. Erlonat Tablets are taken orally as prescribed. The dose and duration of treatment are determined by the patient's diagnosis, molecular testing results (where applicable), overall health, and response to therapy. Key Benefits Contains Erlotinib, an EGFR tyrosine kinase inhibitor. Oral tablet formulation for convenient daily administration. Used as part of targeted treatment strategies for selected cancers. Helps inhibit the growth and spread of EGFR-dependent cancer cells. Manufactured according to high pharmaceutical quality standards. Indications Erlonat Tablets may be prescribed for the treatment of: Non-Small Cell Lung Cancer (NSCLC) with appropriate EGFR mutations, as determined by molecular testing. Pancreatic cancer, in combination with gemcitabine, in selected patients according to approved treatment guidelines. Treatment decisions should be made by a qualified oncology specialist based on the patient's clinical condition and current medical guidelines. Administration Take orally once daily, exactly as prescribed by your healthcare provider. Take the tablet on an empty stomach (at least 1 hour before or 2 hours after a meal). Swallow the tablet whole with water; do not crush or chew. Continue treatment unless instructed otherwise by your physician. Regular monitoring of treatment response and side effects is recommended.

Enazumide Capsules 40mg contains Enzalutamide 40mg, a prescription androgen receptor inhibitor used in the treatment of prostate cancer. It works by blocking the effects of male hormones (androgens), such as testosterone, which can promote the growth of prostate cancer cells. Enzalutamide is commonly prescribed for eligible patients with advanced or metastatic prostate cancer under the supervision of an experienced oncologist. Enazumide is taken orally as directed by a healthcare professional. The dosage and duration of treatment depend on the patient's condition, stage of disease, and overall treatment plan. Key Benefits Contains Enzalutamide 40mg, an androgen receptor inhibitor. Helps inhibit the growth and spread of prostate cancer cells. Oral capsule formulation for convenient daily administration. Used as part of established prostate cancer treatment strategies. Manufactured according to high pharmaceutical quality standards. Indications Enazumide Capsules 40mg may be prescribed for the treatment of: Metastatic Castration-Resistant Prostate Cancer (mCRPC) Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC) Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Treatment is initiated and monitored by an oncology specialist based on the patient's clinical condition and current treatment guidelines. Administration Take orally once daily, exactly as prescribed by your healthcare provider. Swallow the capsules whole with water; do not crush, chew, or open them. Can be taken with or without food. Continue treatment unless instructed otherwise by your physician. Regular monitoring and follow-up appointments are important throughout therapy.

Dazine (Dacarbazine Injection) is a prescription chemotherapy medicine containing Dacarbazine, an alkylating antineoplastic agent used in the treatment of certain types of cancer. It works by interfering with the DNA of rapidly dividing cancer cells, helping to slow or stop their growth. Dazine is commonly used as part of combination chemotherapy regimens and should only be administered under the supervision of experienced oncology specialists. Dazine is supplied as a sterile injectable formulation for intravenous (IV) administration in hospitals and specialized cancer treatment centers. The dosage and treatment schedule are individualized based on the patient's diagnosis, body surface area, overall health, and treatment protocol. Key Benefits Contains Dacarbazine, a well-established chemotherapy agent. Used in standard oncology treatment protocols. Administered by qualified healthcare professionals. Sterile injectable formulation for hospital and clinical use. Manufactured to meet high pharmaceutical quality standards. Indications Dazine (Dacarbazine Injection) may be prescribed for the treatment of: Metastatic malignant melanoma (advanced melanoma) Hodgkin lymphoma, typically as part of combination chemotherapy regimens such as ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine). Treatment decisions are made by an oncologist based on the patient's specific condition and current clinical guidelines. Administration For intravenous (IV) use only. Administered exclusively by trained healthcare professionals. Patients require regular monitoring of blood counts, liver function, kidney function, and overall health throughout therapy. The dose and frequency are determined by the treating oncologist.

Dactinoz (Dacarbazine Injection) is a prescription chemotherapy medicine containing Dacarbazine, an alkylating agent used to treat certain types of cancer. It works by damaging the DNA of rapidly dividing cancer cells, helping to slow or stop their growth. Dacarbazine is commonly used as part of combination chemotherapy regimens under the supervision of experienced oncology specialists. It is administered in hospitals or specialized cancer treatment centers. (medlineplus.gov) Dactinoz is given by intravenous (IV) infusion by qualified healthcare professionals. The dosage and treatment schedule are determined by the oncologist based on the patient's cancer type, body surface area, overall health, and treatment protocol. Key Benefits Contains Dacarbazine, a well-established anticancer medicine. Used in combination chemotherapy regimens for selected cancers. Administered under specialist oncology supervision. Sterile injectable formulation for hospital use. Indications Dactinoz (Dacarbazine Injection) may be prescribed for the treatment of: Metastatic malignant melanoma (advanced skin cancer) Hodgkin lymphoma, typically as part of combination regimens such as ABVD (Adriamycin, Bleomycin, Vinblastine, and Dacarbazine). (medlineplus.gov) Administration For intravenous (IV) use only. Must be administered by trained healthcare professionals in an oncology setting. Regular monitoring of blood counts, liver function, kidney function, and overall clinical condition is required during treatment due to the potential for serious side effects. Storage Store according to the manufacturer's recommendations. Protect from light where specified, and keep out of reach of children. Reconstitution and handling should be performed using appropriate cytotoxic safety precautions. Important: Dactinoz (Dacarbazine Injection) is a prescription-only chemotherapy medicine. It should only be used under the guidance of a qualified oncologist with appropriate monitoring for safety and treatment response.

Bicalutaz Tablet contains Bicalutamide, a non-steroidal anti-androgen (NSAA) medicine primarily used in the treatment of prostate cancer. It works by blocking the action of male hormones (androgens), especially testosterone, which can stimulate the growth of prostate cancer cells. Generic Name: Bicalutamide Therapeutic Category: Anti-androgen / Hormonal Cancer Therapy Uses: Bicalutaz Tablet is used for: Treatment of prostate cancer Management of advanced or metastatic prostate cancer Often used along with LHRH (luteinizing hormone-releasing hormone) agonist therapy to reduce androgen stimulation of cancer cells How It Works: Bicalutamide blocks androgen receptors on prostate cancer cells. By preventing testosterone and other male hormones from activating these receptors, it helps slow down the growth and spread of androgen-dependent prostate cancer cells. Key Benefits: Helps reduce the effect of testosterone on prostate cancer cells Supports hormonal therapy for prostate cancer management May help control disease progression in hormone-sensitive prostate cancer Common Strengths Available: Bicalutamide 50 mg Tablet Bicalutamide 150 mg Tablet Common Side Effects: Possible side effects may include: Hot flashes Breast tenderness or enlargement Reduced sexual desire Fatigue Nausea Changes in liver function tests